DEFA14A: STAAR Surgical Merger Price Boosted to $30.75 Amid Shareholder Vote

STAAR Surgical Company's merger agreement with Alcon has been amended, increasing the cash consideration for stockholders to $30.75 per share, up from $28.00, ahead of a crucial shareholder vote.

Summary

• The merger consideration payable to STAAR Surgical Company (STAAR) stockholders has been increased from $28.00 to $30.75 per share in cash, without interest, subject to withholding taxes.
• The go-shop period, which expired on December 6, 2025, at 11:59 p.m. Eastern Time, did not result in any alternative acquisition proposals, despite STAAR and its financial advisor, Citi, engaging with 21 parties.
• STAAR RSU Awards and STAAR PSU Awards will be converted into restricted stock unit awards of Alcon Inc. ordinary shares, with STAAR PSU Award performance deemed earned at 100% of target.
• The Second Amendment eliminates STAAR's ability to pay any 280G gross-ups and enter into related tax indemnification arrangements in connection with the Merger.
• The STAAR Board of Directors approved the Second Amendment, determining the amended Merger Agreement and transactions are advisable, fair, and in the best interests of STAAR and its stockholders.
• A Special Meeting is scheduled for December 19, 2025, at 8:30 a.m. Pacific Time, for stockholders to vote on the Merger Proposal and the Compensation Proposal.
• Broadwood Partners, L.P., holding approximately 30.2% of STAAR's outstanding shares, and Yunqi Capital Limited, holding 5.1%, intend to vote against the Merger Proposal.
• Regulatory approvals for the merger have been received or confirmed, except for China, Portugal, and Turkey.

Sentiment

Score: 7

Explanation: The increased merger consideration is a clear positive for shareholders, reflecting a better outcome than the original offer. However, significant shareholder opposition and the failure of the go-shop period to attract other bidders introduce uncertainty and suggest potential underlying issues or a lack of broader market interest at a higher valuation.

Positives

• The merger consideration for stockholders increased by $2.75 per share, from $28.00 to $30.75, representing a 9.8% increase.
• The new offer price of $30.75 per share represents a 74% premium to the 90-day volume-weighted average price and a 66% premium to the closing price of STAAR common stock on August 4, 2025, when the original merger agreement was announced.
• STAAR RSU Awards and STAAR PSU Awards will be converted into Alcon Inc. restricted stock unit awards, with PSU performance deemed earned at 100% of target, providing clarity and value for equity holders.
• Most required regulatory approvals have been secured, with only China, Portugal, and Turkey remaining outstanding, indicating significant progress towards closing the transaction.

Negatives

• The Second Amendment eliminates STAAR's ability to pay 280G gross-ups and related tax indemnification arrangements, which could negatively impact executive compensation.
• Significant stockholder opposition exists, with Broadwood Partners, L.P. (30.2% ownership) and Yunqi Capital Limited (5.1% ownership) publicly stating their intent to vote against the Merger Proposal, creating uncertainty for the merger's approval.
• The go-shop period, which involved engagement with 21 parties, expired without any alternative acquisition proposals being submitted, suggesting a lack of competitive interest at a higher valuation.
• A dissenting director on the Board expressed the view that the less than 10% price improvement did not sufficiently address stockholder concerns regarding the sale process and the go-shop.
• A proxy contest initiated by Broadwood Group will lead to additional solicitation and other costs for STAAR and may impair the company's ability to secure the necessary votes for the merger.

Risks

• The consummation of the Merger is subject to the approval of the Merger Agreement by holders of a majority of STAAR's outstanding common stock, which is at risk due to significant opposition from large stockholders like Broadwood (30.2%) and Yunqi Capital (5.1%).
• Failure to obtain certain required regulatory approvals (specifically China, Portugal, and Turkey) or failure to satisfy any other closing conditions could delay or prevent the completion of the proposed transaction.
• The proposed transaction may disrupt management's attention from STAAR's ongoing business operations.
• The announcement of the proposed transaction could affect STAAR's ability to retain and hire key personnel and maintain relationships with its customers, suppliers, and other business partners.
• STAAR's stock price may decline significantly if the proposed transaction is not consummated.
• The proxy contest resulting from the Broadwood Group filing will cause STAAR stockholders to incur additional solicitation and other costs, and may impair STAAR's ability to obtain the votes required to approve the Merger Proposal and Compensation Proposal.

Future Outlook

The filing primarily focuses on the impending merger with Alcon and the updated terms. It reiterates the Board's recommendation for the amended merger agreement and highlights the upcoming Special Meeting on December 19, 2025, where stockholders will vote on the Merger Proposal and the Compensation Proposal. It also outlines the conversion of STAAR equity awards into Alcon shares post-merger. Forward-looking statements emphasize risks related to the merger's completion, including obtaining remaining regulatory approvals (China, Portugal, Turkey), potential disruption to management and business operations, challenges in retaining key personnel, and the possibility of a significant decline in STAAR's stock price if the transaction is not consummated.

Management Comments

• The STAAR Board of Directors approved the Second Amendment after careful consideration and deliberation and determined that the Merger Agreement and the transactions contemplated thereby, as amended by the Amendments, including the Merger, are advisable, fair to and in the best interests of STAAR and its stockholders.
• The Board members voting in favor of such approval and recommendation noted the considerations summarized above, including the opposition of certain stockholders to the Merger, and acknowledged the Board's obligation to obtain the highest value reasonably obtainable for all stockholders.
• They expressed the view that the proposed $30.75 per share in Merger Consideration reflected an increase in price of approximately 9.8% from $28.00 per share, which resulted in greater value to all STAAR stockholders, and approved the Second Amendment.
• The dissenting director expressed the view that the revised considerations contemplated by the Second Amendment, including a less than 10% price improvement, did not sufficiently address STAAR stockholders previously expressed concerns regarding the transaction, including concerns about the sale process and the go-shop.

Industry Context

This filing is highly specific to a corporate acquisition within the medical device and ophthalmology sector, detailing the process and updated terms of STAAR Surgical's merger with Alcon. It highlights the dynamics of an M&A transaction, including the execution of a go-shop period that failed to attract alternative bidders, and subsequent negotiations leading to an increased offer from the original acquirer. The context is primarily focused on the specific transaction rather than broader industry trends, although Alcon's position as a major player in the ophthalmology market provides the backdrop for this strategic acquisition.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or results within the industry. The analysis is focused on the premium offered relative to STAAR's historical stock price and the internal decision-making process of the Board.

Corporate Governance

Legal Proceedings

• The filing mentions the risk of 'the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction,' indicating potential future litigation, but does not detail any specific ongoing legal proceedings beyond the proxy contest initiated by Broadwood Group.

Stakeholder Impact

• **Shareholders**: Will receive an increased cash consideration of $30.75 per share if the merger is approved. Those holding equity awards will have them converted into Alcon shares. However, significant shareholders (Broadwood, Yunqi) are opposing the merger, creating uncertainty.
• **Employees**: Equity awards (RSUs, PSUs) will be converted into Alcon restricted stock units, with PSU performance deemed at 100% target. The elimination of 280G gross-ups could impact executive compensation. Management noted potential impact on employee retention and morale due to proposed changes to equity awards.
• **Management**: Executive officers are eligible for significant severance payments and benefits upon a qualifying termination in connection with the merger, as detailed in the compensation table.

Next Steps

• Stockholders are urged to vote on the Merger Proposal and the Compensation Proposal at the Special Meeting scheduled for December 19, 2025.
• The merger's completion is contingent upon stockholder approval and the receipt of remaining regulatory approvals from China, Portugal, and Turkey.
• Upon the Effective Time of the merger, STAAR common stock will be converted into cash, and equity awards will be converted into Alcon shares.

Key Dates

Recommendation

While the increased offer price of $30.75 per share is a positive development for shareholders, the significant opposition from major stockholders (Broadwood and Yunqi Capital, representing over 35% of outstanding shares combined) introduces substantial uncertainty regarding the merger's approval. The failure of the go-shop period to attract alternative bidders also suggests that a higher offer from another party is unlikely. Given the current stock price of $23.54 (as of Dec 8, 2025) is well below the offer price, there's an arbitrage opportunity if the merger goes through. However, the strong opposition makes the outcome uncertain. A 'hold' recommendation acknowledges the potential upside if the merger closes, but also the downside risk if it fails due to shareholder dissent, which could see the stock revert to pre-merger announcement levels or lower. Investors should monitor the outcome of the Special Meeting closely.

Keywords

STAAR Surgical, Alcon, Merger Agreement, Proxy Statement, Acquisition, Shareholder Vote, Merger Consideration, Go-Shop, Equity Awards, Corporate Governance, Regulatory Approvals, Stockholder Opposition, DEFA14A